Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operating highlights for the third quarter ended September 30, 2014. The Company’s lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat bacterial infections, including those caused by many of the multidrug-resistant (MDR) Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention.
Help employers find you! Check out all the jobs and post your resume.
